- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06042270
Firefighter Thermoregulatory Responses in Active Fire With Betaine Supplementation (FFBET)
April 3, 2024 updated by: Michael J. Ormsbee
Thermoregulatory Responses of Betaine Supplementation in Firefighters During Live Burn
The goal of this clinical trial is to compare betaine supplementation to placebo in firefighters undergoing live burn training regarding thermoregulation and inflammation. The main questions it aims to answer are:
- Does betaine supplementation mitigate rises in core temperature during firefighter live burn training?
- Does betaine supplementation decrease inflammation from firefighter training?
- Does betaine supplementation increase total body water stores?
Participants will supplement with betaine for 1 month and complete:
- Total Body Water measures
- Body Composition measures
- Live Burn training with Core Temperature Measurements
- Provide Salivary samples
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Liliana Renteria
- Phone Number: 8506451016
- Email: lir20@fsu.edu
Study Contact Backup
- Name: Michael Ormsbee, PhD
- Email: mormsbee@fsu.edu
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32301
- Institute of Sports Science and Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Structural Firefighter
Exclusion Criteria:
• Participants have a cardiometabolic disease for which they take prescribed medications
- Participants consume supplements known to impact hydration status or performance that they are not willing to stop taking for the study
- Participants are pregnant
- Female participants that have irregular menstrual cycles
- Participants are injured and would not be able to fulfill the live burn scenario
- Participants have sickle cell disease
- Participants have experienced heat stroke within the last 2 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
10 participants will be given rice-flour as a placebo
|
3 grams per day for ~4 weeks
Other Names:
|
Active Comparator: Betaine
10 participants will be given betaine
|
3 grams per day for ~4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thermoregulation
Time Frame: 10 minutes before the live burn, during the ~15 minute live burn, 10, 20, and 30 minutes after the live burn.
|
Core temperature (Degrees C), skin temperature (Degrees C)
|
10 minutes before the live burn, during the ~15 minute live burn, 10, 20, and 30 minutes after the live burn.
|
Stress (enzyme linked immunoassays)
Time Frame: before, immediately after, 10 minutes, and 20 minutes after live burn
|
Salivary expression of Testosterone, Cortisol, interleukin-8, and interleukin 6 will be measured.
|
before, immediately after, 10 minutes, and 20 minutes after live burn
|
Stress (respiration efficiency)
Time Frame: immediately before and immediately after the completion of the live burn
|
Air tank pounds per square inch (PSI) will be recorded
|
immediately before and immediately after the completion of the live burn
|
Sweat Rate
Time Frame: immediately before and immediately after the completion of the live burn
|
Changes in body weight in kg will be used to find loss of sweat in L
|
immediately before and immediately after the completion of the live burn
|
Sweat Content
Time Frame: immediately before and immediately after the completion of the live burn
|
Tegaderm patches will be worn during the live burn to analyze sodium concentration in sweat.
|
immediately before and immediately after the completion of the live burn
|
Subjective measures
Time Frame: immediately before and immediately after the completion of the live burn
|
Visual analog scales will be given to participants for subjective thermal sensation, rate of perceived exertion, and thirst
|
immediately before and immediately after the completion of the live burn
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronic Stress (enzyme linked immunoassays)
Time Frame: Before supplementation and after 4 weeks of supplementation
|
Saliva will be analyzed for testosterone, cortisol, uric acid, and c-reactive protein
|
Before supplementation and after 4 weeks of supplementation
|
Chronic Stress (vitals) professional firefighters.
Time Frame: Before supplementation and after 4 weeks of supplementation
|
Resting blood pressure in mmHg and heart rate in beats per minute will be measured.
|
Before supplementation and after 4 weeks of supplementation
|
Fluid Compartment Volumes (Bioelectrical Impedance Spectrocopy) professional firefighters.
Time Frame: Before supplementation and after 4 weeks of supplementation
|
Intracellular fluid volume (L), extracellular fluid volume (L), plasma volume (L), total body water (L)
|
Before supplementation and after 4 weeks of supplementation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 20, 2023
Primary Completion (Actual)
March 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
August 25, 2023
First Submitted That Met QC Criteria
September 11, 2023
First Posted (Actual)
September 18, 2023
Study Record Updates
Last Update Posted (Actual)
April 4, 2024
Last Update Submitted That Met QC Criteria
April 3, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004218
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States